A Comprehensive Board Review in Hematology and Medical Oncology

—A Virtual Live Streaming Course—

September 27-October 2, 2021

September 27-29, 2021: Benign and Malignant Hematology

September 28-October 2, 2021: Malignant Hematology and Solid Tumor









A Comprehensive Board Review in Hematology and Medical Oncology

— A Virtual Live Streaming Course —

GOAL

The course is a 6-day comprehensive review of current standards and practices in the management of patients with blood disorders and malignancy. The course is designed to enable the participant to effectively prepare for the American Board of Internal Medicine certification and recertification examinations in Hematology and Medical Oncology. Advances in clinical pharmacology, molecular genetics and risk assessment, and radiation oncology will be included.

EDUCATIONAL OBJECTIVES

At the conclusion of this educational activity, participants should be able to:

- Apply knowledge gained to prepare for the hematology and medical oncology subspecialty and recertification examinations in hematology and medical oncology
- Utilize current standards of care for patients with cancer, blood disorders and malignancies
- Demonstrate proficiency of knowledge in hematology and medical oncology
- Incorporate recent advances in management of hematologic and oncologic patients; and
- Define molecular determinants of cancer risk and apply this knowledge in practice.

TARGET AUDIENCE

This program should be of interest to Physicians, Advanced Practice Providers, APNs, and Nurses.

EDUCATIONAL METHODS

- Lectures/Didactic
- Case-based Question-and-Answer Sessions (in board examination format)
- Virtual Live Streaming Course
- · Canvas an online course management system

EVALUATION

A course evaluation survey will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

ACCREDITATION/CREDIT DESIGNATION

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 51.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC POINTS

American Board of Internal Medicine



Successful completion of this CME activity, which includes participation in the evaluation component,

enables the participant to earn up to 51.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points. In order to receive MOC points, you must pass the post-test with a score of 70% or higher.

Participant completion data will be shared with and transmitted to the ACCME on the participant's behalf.

Please Note: The deadline to claim MOC Points and CME Credits is November 2, 2021.

CME CERTIFICATES AND ATTENDANCE **VERIFICATION CERTIFICATES**

Certificates awarding AMA PRA Category 1 Credit™ or certificates documenting attendance will be available to participants once they complete the on-line evaluation. To obtain a CME certificate, physicians must complete the on-line evaluation questionnaire.

A record of attendance (certificate) will be available online to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

PLANNING COMMITTEE

MD Anderson Cancer Center

Sharon Giordano, MD, MPH, Co-Chair Tapan Kadia, MD, Co-Chair Bonnie Glisson, MD, FACP

Shreyaskumar Patel, MD Alessandra Ferrajoli, MD Nishin Bhadkamkar, MD Felisha Estelle

Baylor College of Medicine Martha Mims, MD, PhD, Co-Chair

AGENDA

Monday, September 27, 2021

| All times are in Central Time (CT) | | |
|------------------------------------|--|--|
| 6:45 am | Virtual On-line Registration Check-in | |
| 7:15 | Welcome and Introduction | |
| | Martha Mims, MD, PhD | |
| | Section Chief, Hematology/Oncology | |
| | Baylor College of Medicine | |
| BENIG | N HEMATOLOGY SESSION | |
| General | Topics/Red Cell Disorders/Platelets | |
| 7:30 | Iron Deficiency and Hemochromatosis Matthew Heeney, MD | |
| 8:15 | Hematopoietic Growth Factors Martha Mims, MD, PhD | |
| 9:00 | Bone Marrow Failure Timothy Olson, MD, PhD | |
| 9:45 | Break | |
| 10:00 | Leukopenia and Leukocytosis Nancy Berliner, MD | |
| 10:45 | Issues in Transfusion Medicine TBA | |
| 11:45 | Q & A Panel Discussion Matthew Heeney, MD; Martha Mims, MD, PhD; Timothy Olson, MD, PhD; and Nancy Berliner, MD | |
| 12:00 pm | Lunch Break | |
| Coagula | tion/Platelets/Red Cell Disorders | |
| 12:30 | Sickle Cell Anemias, Thalassemia, and Hemoglobinopathies Alice Ma, MD | |
| 1:15 | Hemolytic Anemias Iberia Romina Sosa, MD, PhD | |
| 2:00 | Approach to Anemia Alice Ma, MD | |
| 2:30 | Break | |
| 2:45 | Disorders of Platelet Function A. Koneti Rao, MD, FACP | |
| 3:30 | Thrombocytopenias Alvin Schmaier, MD | |
| 4:15 | Q & A Panel Discussion Alice Ma, MD; Iberia Romina Sosa, MD, PhD; A. Koneti Rao, MD, FACP; and Alvin Schmaier, MD | |
| 4:30 | Adjourn | |

Tuesday, September 28, 2021

All times are in Central Time (CT)

| Platelet/Red | Cell Disorders/ | Transfusion Medicine |
|--------------|-----------------|-----------------------------|
|--------------|-----------------|-----------------------------|

| 7:30 am | Antithrombotic & Antiplatelet Therapy Alvin Schmaier, MD |
|---------|---|
| 8:15 | Normal Coagulation Kenneth Bauer, MD |
| 9:00 | Break |
| 9:15 | Coagulation Factor Deficiencies, Including von Willebrand's Disease and Hemophilias Kenneth Bauer, MD |
| 10:00 | Hypercoagulable States Stephan Moll, MD |
| 11:00 | Q & A Panel Discussion Alvin Schmaier, MD; Kenneth Bauer, MD; and Stephan Moll, MD |
| 11:15 | Benign Hematology Q & A Session Jahnayi Gollamudi, MD |

MALIGNANT HEMATOLOGY SESSION

Lymphoma/Leukemia 12:30 pm **Classification of Lymphoma**

Lunch Break

11:55

| | Lynne Abruzzo, MD, PhD |
|------|--|
| 1:15 | Aggressive Non-Hodgkin Lymphoma Loretta Nastoupil, MD |
| 2:00 | Break |
| 2:15 | Indolent Non-Hodgkin Lymphoma Nathan Fowler, MD |
| 3:00 | Hodgkin Lymphoma Barbara Pro, MD |
| 3:45 | Acute Lymphoblastic Leukemia Daniel DeAngelo, MD, PhD |
| 4:30 | Q & A Panel Discussion Lynne Abruzzo, MD, PhD; Loretta Nastoupil, MD; Nathan Fowler, MD; Barbara Pro, MD; and Daniel DeAngelo, MD, PhD |
| 4:45 | Adjourn |
| | |

Wednesday, September 29, 2021

All times are in Central Time (CT)

| Mycloma, Leukemia, MD3 | | |
|------------------------------------|---|--|
| 7:30 am | Multiple Myeloma and Other Plasma Cell Dyscrasias | |
| | S. Vincent Rajkumar, MD | |
| 8:30 | Chronic Lymphocytic Leukemia and Hairy Cell Leukemia Susan O'Brien, MD | |
| 9:15 | Chronic Myeloid Leukemia | |
| | Jorge Cortes, MD | |
| 10:00 | Break | |
| 10:15 | Myelodysplastic Syndrome | |
| | Tapan Kadia, MD | |
| 11:00 | Acute Myeloid Leukemia | |
| | Courtney DiNardo, MD | |
| 11:45 | Q & A Panel Discussion | |
| | S. Vincent Rajkumar, MD; Susan O'Brien, MD; Jorge Cortes, MD; Tapan Kadia, MD; and | |
| | Courtney DiNardo, MD | |
| 12:00 pm | Malignant Hematology Q & A Session | |
| 1 | Kelly Chien, MD | |
| 12:40 | Lunch Break | |
| MPNs/Transplant/Infectious Disease | | |
| 1:15 | Myleoproliferative Neoplasms | |
| | Cudan Vanatarrada MD | |

| 1.13 | Srdan Verstovsek, MD |
|------|---|
| 2:15 | Stem Cell Transplant Supportive Care Betty Hamilton, MD |
| 3:15 | Break |
| 3:30 | Infectious Complications in Cancer Patients Samuel Shelburne, MD, PhD |
| 4:15 | Q & A Panel Discussion Srdan Verstovsek, MD; Betty Hamilton, MD; and Samuel Shelburne, MD, PhD |
| 4:30 | Adjourn |

Thursday, September 30, 2021

Pharmacology/Genetic Risk Factors/Neuro-Oncology 7:30 am Pharmacology I: Chemotherapy

All times are in Central Time (CT)

SOLID TUMOR SESSION

Histologies
Shannon Westin, MD
Q & A Panel Discussion

Mark Lewis, MD

Adjourn

4:30

4:45

5:25

| , | Chrystia Zobniw, PharmD |
|---|---|
| 8:30 | Pharmacology II: Targeted Therapy (Alk, EGFR, VEGR, HER2, HH, mTOR, PARP) Whitney Lewis, PharmD |
| 9:00 | Pharmacology III: Targeted Therapy (CD20, CD30, CD33, Proteasome, BCR-ABL/KIT, FLT3, IDH1/2, CDK4/6, PI3K) Brian Primeaux, PharmD |
| 9:30 | Break |
| 9:45 | Pharmacology IV: Immunotherapy Chrystia Zobniw, PharmD |
| 10:05 | Genetic Risk Factors Claudine Isaacs, MD |
| 10:50 | Neuro-Oncology Antonio Omuro, MD |
| 11:35 | Q & A Panel Discussion Chrystia Zobniw, PharmD; Claudine Isaacs, MD; Whitney Lewis, PharmD; Brian Primeaux, PharmD; and Antonio Omuro, MD |
| 11:50 | Lunch Break |
| Melanoma/Sarcoma/Gynecologic Oncology | |
| 12:15 pm | Melanoma Rodabe Amaria, MD |
| 1:00 | Sarcoma Shreyaskumar Patel, MD |
| 2:00 | Cervical Cancer Alejandro Rauh Hain, MD |
| 2:45 | Break |
| 3:00 | Uterine Cancer Shannon Westin, MD |
| 3:30 | Ovarian Cancer and Unusual Ovarian |

Rodabe Amaria, MD; Shreyaskumar Patel, MD; Alejandro Rauh Hain, MD; and Shannon Westin, MD

Pharmacology/Genetic Risk Factors/Neuro-Oncology/Melanoma/Sarcoma/GYN

Solid Tumor Q & A - Session 1:

Friday, October 1, 2021

All times are in Central Time (CT)

| Breast Cancer | | |
|----------------------|--|--|
| 7:30 am | Screening/Local Management of Breast Cancer Jennifer Litton, MD | |
| 8:15 | Systemic Treatment of Primary Breast Cancer Including HER2 Positive Breast Disease Lisa Carey, MD | |
| 9:15 | Break | |
| 9:30 | Treatment of Metastatic Breast Cancer Including HER2 Positive Breast Disease Mariana Chavez MacGregor, MD | |
| 10:30 | Special Issues in Breast Cancer Sharon Giordano, MD | |
| 11:00 | Q & A Panel Discussion Jennifer Litton, MD; Lisa Carey, MD; Mariana Chavez MacGregor, MD; and Sharon Giordano, MD | |
| 11:15 | ASH/ASCO Choosing Wisely Recommendations Ravin Garg, MD | |
| 11:55 | Lunch Break | |
| Lung Ca | ncer/Head and Neck Cancer/Thyroid Cancer | |
| 12:25 pm | Charles A. Koller, MD Lectureship Award 2021 Recipient: Nasser Hanna, MD | |
| 12:30 | Early Stage and Locally Advanced Non-Small Cell Lung Cancer Nasser Hanna, MD | |
| 1:15 | Metastatic Non-Small Cell Lung Cancer Nasser Hanna, MD | |
| 2:15 | Small Cell Lung Cancer Lauren Byers, MD | |
| 2:45 | Break | |
| 3:00 | Head and Neck Cancer William N. William, Jr., MD | |
| 3:45 | Thyroid Cancer Naifa Busaidy, MD | |
| 4:15 | Q & A Panel Discussion Nasser Hanna, MD; Lauren Byers, MD; William N. William, Jr., MD; and Naifa Busaidy, MD | |
| 4:30 | Solid Tumor Q & A - Session 2: Breast Cancer/Lung Cancer/Head and Neck Cancer/ Thyroid Cancer Tina Cascone, MD, PhD | |
| 5:10 | Adjourn | |

Saturday, October 2, 2021

All times are in Central Time (CT)

| Gastrointestina | l Onco | logy |
|-----------------|--------|------|
|-----------------|--------|------|

| 7:30 am | Pancreaticobiliary Cancers/Unknown Primary Robert Wolff, MD | |
|-------------------------------|--|--|
| 8:30 | Gastroesophageal Cancers/ Hepatocellular Carcinoma Harry Yoon, MD | |
| 9:30 | Break | |
| 9:45 | Colorectal Cancer: Biology and Adjuvant Therapy Scott Kopetz, MD, PhD | |
| 10:15 | Metastatic Colorectal Cancer and Anal Cancer Scott Kopetz, MD, PhD | |
| 11:15 | Q & A Panel Discussion Robert Wolff, MD; Harry Yoon, MD; and Scott Kopetz, MD, PhD | |
| 11:30 | Lunch Break | |
| Genitourinary Oncology | | |
| | Testicular Cancer Timothy Gilligan, MD | |
| 1:00 | Urothelial Cancer | |

| 12:00 pm | Testicular Cancer |
|----------|--|
| | Timothy Gilligan, MD |
| 1:00 | Urothelial Cancer Arlene Siefker-Radtke, MD |
| 1:45 | Renal Cell Carcinoma Eric Jonasch, MD |
| 2:30 | Break |
| 2:45 | Prostate Cancer Nicholas Mitsiades, MD, PhD |
| 4:00 | Q & A Panel Discussion Timothy Gilligan, MD; Arlene Siefker-Radtke, MD; Eric Jonasch, MD; and Nicholas Mitsiades, MD, PhD |
| 4:15 | Solid Tumor Q & A - Session 3: Gastrointestinal Oncology/Genitourinary Oncology Ravin Garg, MD |
| 4:55 | Adjourn |

Guest Faculty

Lynne Abruzzo, MD, PhD

The Ohio State University Columbus, Ohio

Kenneth Bauer, MD

Beth Israel Deaconess Medical Center Boston, Massachusetts

Nancy Berliner, MD

Brigham and Women's Hospital Boston, Massachusetts

Lisa Carey, MD

UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina

Jorge Cortes, MD

Gerogia Cancer Center Augusta, Atlanta

Daniel DeAngelo, MD, PhD

Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts

Ravin Garg, MD

Johns Hopkins University Maryland Oncology Hematology -Annapolis Division Annapolis, Maryland

Timothy Gilligan, MD

Cleveland Clinic Cleveland, Ohio

Betty Hamilton, MD

Cleveland Clinic Cleaveland, Ohio

Nasser Hanna, MD

Indiana University School of Medicine Indianapolis, Indiana

Matthew Heeney, MD

Dana-Farber/Boston Children's Cancer and Blood Disorders Center Boston, Massachusetts

Claudine Isaacs, MD

Georgetown University Washington, District of Columbia

Mark Lewis, MD

Intermountain Healthcare Murray, Utah

Alice Ma, MD

University of North Carolina – Chapel Hill School of Medicine Chapel Hill, North Carolina

Stephan Moll, MD

University of North Carolina School of Medicine Chapel Hill, North Carolina

Susan O'Brien, MD

University of California, Irvine Irvine, California

Timothy Olson, MD, PhD

Children's Hospital of Philadelphia Philadelphia, Pennsylvania

Antonio Omuro, MD

Yale Cancer Center New Haven, Connecticut

Barbara Pro, MD

Robert H. Lurie Cancer Center Northwestern University-Feinberg School of Medicine Chicago, Illinois

S. Vincent Rajkumar, MD

Mayo Clinic – Minnesota Rochester, Minnesota

A. Koneti Rao, MD, FACP

Lewis Katz School of Medicine at Temple University Philadelphia, Pennsylvania

Alvin Schmaier, MD

Case Western Reserve University Cleveland, Ohio

Iberia Romina Sosa, MD, PhD

Fox Chase Cancer Center Philadelphia, Pennsylvania

William William, Jr., MD

BP Hospital Sao Paulo, Brazil

Harry Yoon, MD

Mayo Clinic – Minnesota Rochester, Minnesota

REGISTRATION INFORMATION

A Virtual Live Streaming Course.

The Comprehensive Board Review in Hematology and Medical Oncology is going virtual. This program will be presented only as a live streaming course. You will receive an email from the course platform to log in and access the live course online approximately a week before the conference.

PRESENTATIONS:

Course syllabus will not be printed. Presentations (slides) will be available online via the course platform and Canvas. The PowerPoint presentations will be posted online as PDFs prior to the conference. You will receive an invitation email with directives to log in Canvas.

- The Full Conference and Hematology Session will begin at 7:30 am on Monday, September 27. The Hematology Session will adjourn at 4:30 pm on Wednesday, September 29. The full conference will adjourn at 4:55 pm on Saturday, October 2.
- The Oncology Session will begin at 12:30 pm on Tuesday, September 28 and adjourn at 4:55 pm on Saturday, October 2.

Advanced registration is encouraged. Please see the registration fees page.

*NOTE: The conference registration fee includes the tuition, access to course virtual platform with PDFs of the slides and Canvas - online web-based system with recorded videos.

The deadline for advanced registration is Friday, September 3, 2021.

Register online at https://mdanderson.cloud-cme.com/hmobr2021

Telephone registrations are not accepted.

We accept the following forms of payment:

- Credit Cards (MasterCard, VISA, and American Express)
- · Check (payable through U.S. banks only)
- Mail to: Continuing Professional Education Unit 1781
 The University of Texas MD Anderson Cancer Center P.O. Box 301407
 Houston, TX 77230-1407

When registering online a receipt (confirmation letter) will be automatically emailed to the e-mail address you list on the registration form.

REFUND/CANCELLATION POLICY

The registration fee, minus a \$50 administrative handling fee, is refundable if a written request is received on or before **Friday**, **September 3, 2021.** No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check. For additional information, contact Continuing Professional Education at 713-792-2223 or toll free at 866-849-5866.

Continuing Professional Education reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form.

In case of activity cancellation, the liability of Continuing Professional Education is limited to the registration fee. Continuing Professional Education will refund the full registration fee.

Continuing Professional Education reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. Please check the website.

PAST CONFERENCES - REVIEWS AND TESTIMONIALS

"The conference was well worth my time. It is nice to be able to take in as much information as possible and have the option of talking to the speakers afterwards. If this board review is still around in ten years (I hope it is), I will certainly attend it again as I study for my recertification."

"Fantastic course! It helped pass my boards with flying colors!"

"As a first time attendee and visitor to MD Anderson, the overall organization and quality of activity was very impressive and met every expectation. Would recommend this activity to any colleague/associate."

"Excellent review course. The conference was well organized and ran smoothly."

"Exceeded expectations; worth every penny."

"Superb conference. Exceptional, impressive"

"Very well organized. Amazing how well support staff kept program on time, and fed everyone."

Please let us know what specific topics, issues, or questions you wish to see addressed or emphasized in this activity by emailing Continuing Professional Education at PEPinfo@mdanderson.org. All responses will be forwarded to the Program Chairs for consideration.

SPECIAL ASSISTANCE

Contact Felisha Estelle in Continuing Professional Education at 713-745-0083 or 1-866-531-MOBR (6627) if you have any ADA accommodation needs.

CONFERENCE REGISTRATION - D123392

Comprehensive Board Review in Hematology and Medical Oncology

September 27-October 2, 2021

CONFERENCE REGISTRATION FEES

| Full Conference - MDs, PhDs, DOs, PharmDs □ Postmarked on or before August 6, 2021 \$1,200 □ Postmarked on or before September 3, 2021 \$1,300 □ Postmarked after September 3, 2021 \$1,400 |
|--|
| Full Conference - Residents/Fellows/MD Anderson Alumni* □ Postmarked on or before August 6, 2021. \$800 □ Postmarked on or before September 3, 2021 \$900 □ Postmarked after September 3, 2021 \$1,000 |
| Hematology Session - 3 days (Monday - Wednesday) MDs, PhDs, DOs, PharmDs ☐ Postmarked on or before August 6, 2021. \$550 ☐ Postmarked on or before September 3, 2021 \$600 ☐ Postmarked after September 3, 2021 \$650 |
| Hematology Session - 3 days (Monday - Wednesday) Residents/Fellows/MD Anderson Alumni* ☐ Postmarked on or before August 6, 2021. \$350 ☐ Postmarked on or before September 3, 2021. \$400 ☐ Postmarked after September 3, 2021. \$450 |
| Oncology Session - 4 ½ days (Tuesday PM - Saturday) MDs, PhDs, DOs, PharmDs Postmarked on or before August 6, 2021. \$650 Postmarked on or before September 3, 2021 \$700 Postmarked after September 3, 2021 \$750 |
| Oncology Session - 4 ½ days (Tuesday PM - Saturday) Residents/Fellows/MD Anderson Alumni* ☐ Postmarked on or before August 6, 2021. \$450 ☐ Postmarked on or before September 3, 2021 \$500 ☐ Postmarked after September 3, 2021 \$550 |
| Advanced Practice Providers/Nurses/Advanced Practice Nurses* |

^{*}A letter of introduction from the program director or chairperson with registration form is required to claim this reduced fee.

Make check to:

The University of Texas MD Anderson Cancer Center

2021 HEMATOLOGY AND MEDICAL ONCOLOGY BOARD REVIEW: COMPREHENSIVE PROGRAM MATERIAL AVAILABLE FOR NON-ATTENDEES

Comprehensive source material can provide you with home-study material designed for fellows-in-training, physicians planning to take the Hematology or Medical Oncology certifying examination, or physicians wishing to review the established standards of care in Hematology or Medical Oncology.

The conference registration fee includes the tuition, access to the course virtual platform with PDFs of the slides and Canvas (online web-based system with recorded videos).

NOTE: The conference will be available through an online course management system (Canvas) where you will be able to view each recorded lecture. The full conference will be available approximately 10 days after the conference adjourns. Instructions for access to Canvas will be provided.

CME Credits and MOC Points are awarded only by attending the virtual live course.

Available option to obtain course material:

CANVAS - online web-based system with recorded videos (Log in instructions will be provided)

- Online site with downloadable audio & videos for the entire 2021 Course
- Each speaker's complete PowerPoint slide presentation (Adobe Acrobat PDF file)
- · Full color, just as presented
- · Each speaker's list of references
- Please allow 2-3 business days to process order before receiving log in instructions

D123392/PS112004

NON ATTENDEES

CANVAS - online system with recorded videos\$1,000.00

Please note: Flash drives are no longer available to purchase.

Telephone orders are not accepted.

 $\textbf{Register online at} \ \underline{\text{https://mdanderson.cloud-cme.com/hmobr2021}}$

ALL SALES ARE FINAL.

Make check or money order payable to: The University of Texas MD Anderson Cancer Center. Please allow 2-3 business days to process order before receiving log in instructions.



The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented.

MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

| Non-Profit Ora | U.S. Postage | PAID | Houston, TX | Permit No. 7052 |
|---|--|-----------------|--------------------------|-----------------|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| The University of Texas MD Anderson Cancer Center | Continuing Professional Education - Unit 1781 1767nn/3n/173397/41 | P.O. Box 301407 | Houston Texas 77230-1407 | |